ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1549

Treatment Patterns for Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data

Paul Dolin1, Danuta Kielar1, Anat Shavit1, Karina Keogh2, Jennifer Rowell1, Chris Edmonds3, Juliana Meyers4, Elizabeth Esterberg4, Tram Nham4 and Stephanie Chen5, 1AstraZeneca, Cambridge, United Kingdom, 2Mayo Clinic, Rochester, MN, 3AstraZeneca, Gaithersburg, MD, 4RTI Health Solutions, Research Triangle Park, NC, 5BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

Meeting: ACR Convergence 2023

Keywords: Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, immune-inflammatory disorder characterized by asthma, eosinophilia, eosinophil-rich granulomatous inflammation, and chronic necrotizing vasculitis of small-to-medium-sized blood vessels. Systemic glucocorticoids (SGCs) and immunosuppressants remain the cornerstone of treatment, even though chronic SGC use increases the risk of side effects. This retrospective analysis of US administrative health insurance claims data (Merative™ MarketScan® databases) evaluated treatment patterns for patients with EGPA.

Methods: Patients with newly diagnosed EGPA from 2017 to 2021 with ≥12 months of continuous pre-diagnosis health plan enrolment and ≥1 inpatient or ≥2 outpatient EGPA-related diagnoses (≥90 days apart, ICD-10-CM code M30.1) were included. Follow-up was from date of first observed EGPA diagnosis (index date; ID) until health plan disenrollment or database end. Use of SGCs, immunosuppressants, and biologics was analyzed, including duration and dosages (for oral medications). Duration of drug therapy was the period of continuous use including the estimated duration of last fill/refill.

Results: 236 patients were included; 57.6% were female and mean (standard deviation [SD]) age at ID was 50.4 (14.5) years. Mean (SD) follow-up duration was 21.7 (14.6) months and 26.3% of patients had ≥30 months of follow up. In the 12 months before ID and at any time after ID, 92.4% of patients were prescribed a SGC (Table). Prednisone was used by 86.0% of patients, with a mean (SD) daily dose of 22.2 (12.7) mg and mean (SD) duration of 11.8 (11.5) months. Of the 236 patients, 91.1% received oral glucocorticoids (OGCs) either before or after ID, 14.0% had continuous use for ≥24 months, the mean (SD) average dose was 22.4 (13.7) mg/day, and 34.0% had a maximum dose ≥60 mg/day for a mean (SD) duration of 1.6 (1.6) months (Figure). Mean (SD) cumulative OGC dose was 6.3 (6.3) g with 25.6% of patients receiving ≥8 g. Among the 154 patients with at least one OGC dose >4 mg/day, OGC dose was tapered to ≤4 mg/day within 60 days of maximum dose and remained ≤4 mg/day for ≥60 days for 39.0% of patients, and OGC was tapered to >4 mg/day with ≥50% reduction in OGC dose and no subsequent increase in dose for ≥60 days for 18.2%; 11.0% did not attempt to taper their dose. Immunosuppressants were used by 40.3% of patients, most commonly azathioprine (18.2%), methotrexate (17.8%), and mycophenolate mofetil (8.1%). Mean (SD) daily dose and treatment duration were 112.4 (39.6) mg and 10.2 (11.2) months for azathioprine, 3.4 (5.5) mg and 15.5 (14.9) months for methotrexate, and 1,644.4 (749.1) mg and 11.7 (11.5) months for mycophenolate mofetil. Biologics were used by 38.6% of patients, with 15.7% using a B-cell targeting therapy (rituximab).

Conclusion: Despite the use of traditional immunosuppressants and biologics by more than one-third of patients with EGPA, the vast majority were prescribed glucocorticoids, with many receiving OGCs for long, continuous periods, and many with a maximum dose ≥60 mg/day. Most patients were unable to maintain reduced OGC doses during the follow-up period suggesting there is a need for better OGC-sparing therapies.

Supporting image 1

Supporting image 2


Disclosures: P. Dolin: AstraZeneca, 3, 11; D. Kielar: AstraZeneca, 3, 11; A. Shavit: AstraZeneca, 3, 11; K. Keogh: AstraZeneca, 12, site PI for an AstraZeneca pharmaceutical trial in asthma; J. Rowell: AstraZeneca, 3, 11; C. Edmonds: AstraZeneca, 3, 11; J. Meyers: AstraZeneca, 12, Employee of RTI Health Solutions, which received funding from AstraZeneca to conduct the study; E. Esterberg: AstraZeneca, 12, Employee of RTI Health Solutions, which received funding from AstraZeneca to conduct the study; T. Nham: AstraZeneca, 12, Employee of RTI Health Solutions, which received funding from AstraZeneca to conduct the study; S. Chen: AstraZeneca, 3, 11.

To cite this abstract in AMA style:

Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg E, Nham T, Chen S. Treatment Patterns for Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/treatment-patterns-for-eosinophilic-granulomatosis-with-polyangiitis-egpa-a-retrospective-analysis-of-us-health-insurance-claims-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-patterns-for-eosinophilic-granulomatosis-with-polyangiitis-egpa-a-retrospective-analysis-of-us-health-insurance-claims-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology